Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel
2000
How MAP2 Affects Pancreatic Tumor Sensitivity to Docetaxel
publication
Author Information
Author(s): Veitia R, David S, Barbier P, Vantard M, Gounon P, Bissery M C, Fellous A
Primary Institution: Institut Pasteur, Paris
Hypothesis
The study investigates the relationship between microtubule associated protein 2 (MAP2) and the sensitivity of pancreatic tumors to docetaxel.
Conclusion
Proteolysis of MAP2 may enhance the antitumor effect of docetaxel in pancreatic tumors.
Supporting Evidence
- MAP2-related peptides are highly expressed in sensitive pancreatic tumors.
- The intensity of immunostaining for MAP2 is lower in refractory tumors.
- Proteolysis of MAP2 increases tubulin assembly into microtubules in the presence of docetaxel.
Takeaway
This study looks at how a protein called MAP2 in pancreatic tumors can affect how well a cancer drug works.
Methodology
The study involved immunohistochemical localization and analysis of proteolytic activity on MAP2 from pancreatic tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website